JP2020530496A5 - - Google Patents

Download PDF

Info

Publication number
JP2020530496A5
JP2020530496A5 JP2020530436A JP2020530436A JP2020530496A5 JP 2020530496 A5 JP2020530496 A5 JP 2020530496A5 JP 2020530436 A JP2020530436 A JP 2020530436A JP 2020530436 A JP2020530436 A JP 2020530436A JP 2020530496 A5 JP2020530496 A5 JP 2020530496A5
Authority
JP
Japan
Prior art keywords
methyl
chlorophenyl
amino
pharmaceutically acceptable
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2020530436A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530496A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/046057 external-priority patent/WO2019032859A1/en
Publication of JP2020530496A publication Critical patent/JP2020530496A/ja
Publication of JP2020530496A5 publication Critical patent/JP2020530496A5/ja
Ceased legal-status Critical Current

Links

JP2020530436A 2017-08-09 2018-08-09 タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤 Ceased JP2020530496A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762543141P 2017-08-09 2017-08-09
US62/543,141 2017-08-09
US201862630581P 2018-02-14 2018-02-14
US62/630,581 2018-02-14
US201862664442P 2018-04-30 2018-04-30
US62/664,442 2018-04-30
PCT/US2018/046057 WO2019032859A1 (en) 2017-08-09 2018-08-09 SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5)

Publications (2)

Publication Number Publication Date
JP2020530496A JP2020530496A (ja) 2020-10-22
JP2020530496A5 true JP2020530496A5 (enExample) 2021-09-16

Family

ID=63405398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020530436A Ceased JP2020530496A (ja) 2017-08-09 2018-08-09 タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤

Country Status (18)

Country Link
US (4) US10570140B2 (enExample)
EP (2) EP3665179B1 (enExample)
JP (1) JP2020530496A (enExample)
KR (1) KR20200036922A (enExample)
CN (1) CN111527099B (enExample)
AU (1) AU2018313910B2 (enExample)
BR (1) BR112020002736A2 (enExample)
CA (1) CA3072439A1 (enExample)
DK (1) DK3665179T3 (enExample)
ES (1) ES2885180T3 (enExample)
IL (1) IL272519B (enExample)
MA (1) MA49840A (enExample)
MX (1) MX2020001598A (enExample)
PL (1) PL3665179T3 (enExample)
PT (1) PT3665179T (enExample)
UA (1) UA126481C2 (enExample)
WO (1) WO2019032859A1 (enExample)
ZA (1) ZA202000773B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020002736A2 (pt) * 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
US10711007B2 (en) 2018-03-14 2020-07-14 Prelude Therapeutics Incorporated Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
DK3765461T3 (da) * 2018-03-14 2023-11-20 Prelude Therapeutics Inc Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2020033285A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021015796A2 (pt) * 2019-02-13 2021-10-13 Prelude Therapeutics, Incorporated Inibidor seletivo de proteína arginina metiltransferase 5 (prmt5)
IL318073A (en) * 2019-03-25 2025-02-01 California Inst Of Techn PRMT5 inhibitors and their uses
EP3946352A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
EP3952874A4 (en) * 2019-04-05 2022-12-28 Prelude Therapeutics, Incorporated SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5
CA3141855A1 (en) * 2019-05-30 2020-12-03 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
KR20220065811A (ko) * 2019-09-18 2022-05-20 프렐루드 테라퓨틱스, 인코포레이티드 단백질 아르기닌 메틸트랜스퍼라제 5(prmt5)의 선택적 억제제
EP4048674A2 (en) * 2019-10-21 2022-08-31 Accent Therapeutics, Inc. Mettl3 modulators
KR20220086628A (ko) * 2019-10-22 2022-06-23 루핀 리미티드 Prmt5 저해제의 약학적 조합물
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
IL300147A (en) 2020-07-31 2023-03-01 Tango Therapeutics Inc History Piperidin-1-yl-N-pyridin-3-yl-2-oxaacetamide is useful for the treatment of MTAP-deficient and/or MTA-accumulating cancer
JP2023543433A (ja) 2020-09-21 2023-10-16 プレリュード・セラピューティクス・インコーポレイテッド Cdk阻害剤及び医薬としてのその使用
US20220251088A1 (en) * 2020-12-10 2022-08-11 Prelude Therapeutics, Incorporated Processes for Making PRMT5 Inhibitors
TW202233183A (zh) * 2020-12-16 2022-09-01 美商安進公司 新型prmt5抑制劑
JP2023554643A (ja) 2020-12-18 2023-12-28 プレリュード・セラピューティクス・インコーポレイテッド Cdk阻害剤及び医薬としてのその使用
CN117157297A (zh) * 2021-07-20 2023-12-01 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
US20230181589A1 (en) * 2021-12-03 2023-06-15 The Trustees Of Indiana University Prmt5 inhibitors for ocular therapy
US11939340B2 (en) 2022-01-21 2024-03-26 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
WO2023150612A1 (en) 2022-02-03 2023-08-10 Prelude Therapeutics, Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2023172957A1 (en) 2022-03-09 2023-09-14 Prelude Therapeutics, Incorporated Thaizole-pyrimdiine cdk inhibitors and their use as pharmaceuticals
CA3245813A1 (en) 2022-03-23 2023-09-28 Prelude Therapeutics Inc POLYMORPHIC COMPOUNDS AND THEIR USES
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
US20240150340A1 (en) 2022-10-06 2024-05-09 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
US20240352029A1 (en) 2023-04-14 2024-10-24 Prelude Therapeutics Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
CN116554194A (zh) * 2023-05-23 2023-08-08 江苏八巨药业有限公司 一种卡培他滨中间体的合成方法
WO2025064402A1 (en) * 2023-09-22 2025-03-27 St. Jude Children's Research Hospital, Inc. Method for treating sickle cell disease by targeting senescent cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
DE102010060118A1 (de) * 2010-10-22 2012-04-26 Röhm Gmbh Stirnseitenmitnehmer
CA2819625A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AR084824A1 (es) * 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
MY199894A (en) * 2012-12-21 2023-11-27 Epizyme Inc Prmt5 inhibitors and uses thereof
EP2970136A1 (en) * 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014145214A2 (en) * 2013-03-15 2014-09-18 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
EP3160466A4 (en) * 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP3212201B1 (en) 2014-10-28 2022-10-19 BCI Pharma Nucleoside kinase inhibitors
KR101719881B1 (ko) * 2014-12-22 2017-03-24 삼성전기주식회사 렌즈 모듈
TN2017000357A1 (en) * 2015-02-24 2019-01-16 Pfizer Substituted nucleoside derivatives useful as anticancer agents
AR104326A1 (es) * 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2017230658B2 (en) 2016-03-10 2021-03-04 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as PRMT5 inhibitors
WO2017218802A1 (en) 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018075601A1 (en) 2016-10-18 2018-04-26 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018085833A2 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyl transferase 5 (prmt5)
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152548A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160855A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112020002736A2 (pt) 2017-08-09 2020-07-28 Prelude Therapeutics, Incorporated inibidores seletivos da proteína arginina metiltransferase 5 (prmt5)
US11524962B2 (en) 2017-10-26 2022-12-13 Prelude Therapeutics, Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein arginine methyl transferase 5 (PRMT5)
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Similar Documents

Publication Publication Date Title
JP2020530496A5 (enExample)
CN114599361B (zh) Prmt5抑制剂的药物组合物
ES2612378T3 (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas como inhibidores de cinasa MKNK
CN102015739B (zh) 化合物以及用于治疗的方法
IL282916B1 (en) Fused cyclic chemical compounds and their uses in the treatment of ras-mediated diorders
US20140357636A1 (en) Treatment of Skeletal-Related Disorders
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
JP7577672B2 (ja) Flt3阻害剤及び低メチル化剤を含む急性骨髄性白血病の治療のための薬学的組成物
ES2639402T3 (es) 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol
RU2006128426A (ru) Производные тиофенав в качестве ингибиторов снк 1
EA012869B1 (ru) Замещённые пиримидины, композиции на их основе и применение замещенных пиримидинов в качестве ингибиторов протеинкиназ
SA111320735B1 (ar) إيميدازوبيريدازينات مستبدلة
JP2016516821A5 (enExample)
US20230053946A1 (en) Combinations
JP2015515961A5 (enExample)
JP2015505816A5 (enExample)
US20230087941A1 (en) Combinations
TW202015693A (zh) 治療pi3k 相關病症之給藥方案
KR20220119442A (ko) 조합
ES2863250T3 (es) Tratamiento de trastornos neurológicos
US20230068370A1 (en) Combinations
KR20220119427A (ko) 조합
US20230054767A1 (en) Combinations
US20230042653A1 (en) Combinations
US20220241310A1 (en) Thiarabine- and thiarabine prodrug-based treatments